Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US-2017362573-A1 · Dec 21, 2017 · US
US9376665B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9376665-B2 |
| Application number | US-201113882904-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2011 |
| Priority date | Nov 2, 2010 |
| Publication date | Jun 28, 2016 |
| Grant date | Jun 28, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.
Opening claim text (preview).
The invention claimed is: 1. A method of producing intestinal cells expressing Cdx2, comprising the steps of: (a) obtaining mouse or human embryonic stem (ES) cells, (b) culturing the ES cells of step (a) with Activin and/or bFGF to produce definitive endoderm cells, (c) culturing the definitive endoderm cells of step (b) with (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) and in the presence of M15 cells or MEF cells, to thereby induce differentiation of the definitive endoderm cells into intestinal cells expressing Cdx2. 2. The method according to claim 1 , wherein the definitive endoderm cells are separated from a cell culture obtained in step (b) by flow cytometry using fluorescently-labelled antibodies against E-cadherin (ECD) and CXCR4, and said separated definitive endoderm cells are used in the step (c). 3. The method according to claim 1 , wherein the ES cells are cultured in the presence of feeder cells. 4. The method according to claim 3 , wherein the feeder cells are cells derived from a mesoderm.
connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts" · CPC title
Endothelial cells · CPC title
Notch; Delta; Jagged; Serrate · CPC title
Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10 · CPC title
Small molecules not provided for elsewhere · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.